Theravance Biopharma, Inc.
TBPH
$16.48
-$0.04-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 394.67M | 315.36M | 329.68M | 338.80M | 130.86M |
| Total Receivables | 15.58M | 95.54M | 18.27M | 21.92M | 15.35M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 7.38M | 7.56M | 6.75M | 5.57M | 4.06M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 417.63M | 418.46M | 354.70M | 366.29M | 150.26M |
|
|
|||||
| Total Current Assets | 417.63M | 418.46M | 354.70M | 366.29M | 150.26M |
| Net Property, Plant & Equipment | 28.54M | 30.27M | 31.71M | 33.13M | 34.46M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 26.14M | 25.72M | 26.03M | 26.61M | 158.86M |
| Total Assets | 472.31M | 485.57M | 415.46M | 426.04M | 343.58M |
|
|
|||||
| Total Accounts Payable | 1.10M | 2.57M | 2.21M | 1.68M | 2.41M |
| Total Accrued Expenses | 14.64M | 19.50M | 20.21M | 15.37M | 12.43M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 10.75M | 10.95M | 10.91M | 10.90M | 10.81M |
| Total Finance Division Other Current Liabilities | 5.29M | 5.29M | 4.07M | 26.70M | 5.85M |
| Total Other Current Liabilities | 5.29M | 5.29M | 4.07M | 26.70M | 5.85M |
| Total Current Liabilities | 31.78M | 38.30M | 37.41M | 54.63M | 31.50M |
|
|
|||||
| Total Current Liabilities | 31.78M | 38.30M | 37.41M | 54.63M | 31.50M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 29.75M | 31.76M | 33.68M | 35.56M | 37.35M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 120.19M | 118.79M | 111.69M | 110.99M | 108.75M |
| Total Liabilities | 181.72M | 188.85M | 182.78M | 201.19M | 177.60M |
|
|
|||||
| Common Stock & APIC | 1.16B | 1.16B | 1.15B | 1.15B | 1.15B |
| Retained Earnings | -864.56M | -859.63M | -920.65M | -924.27M | -979.10M |
| Treasury Stock & Other | -62.00K | 61.00K | 32.00K | -10.00K | -- |
| Total Common Equity | 290.59M | 296.72M | 232.68M | 224.85M | 165.98M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 290.59M | 296.72M | 232.68M | 224.85M | 165.98M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 290.59M | 296.72M | 232.68M | 224.85M | 165.98M |
|
|
|||||